12,372 trials
Chronic Cluster Headache
Primary: Overall Mean Change From Baseline in Weekly Cluster Headache Attack Frequency — -4.59; -5.38 cluster headache attacks per week — p=0.334
Hyperlipidemia and Mixed Dyslipidemia
Primary: Number of Participants With Adverse Events — 796; 1655; 929; 1789 Participants
Cataract
Primary: Anterior Chamber Inflammation — .913; .783 grade of anterior chamber cells
Eales' Disease
Primary: Change in OCT Thickness. — 269; 262 um
Epilepsy, Partial
Primary: Partial (Type I) Seizure Frequency Per Week by Analysis Visit — 1.68; 2.19; 1.69; 2.00 Number of Seizures (Type I) per week
Non-operable Chronic Thromboembolic Pulmonary Hypertension
Primary: Change in 6-minute Walk Test Distance After 24 Weeks — 45.43; 3.83 m — p=0.002
Cervical Intraepithelial Neoplasia
Primary: Number of Seropositive Subjects for Anti-HPV-16 Antibodies at Day 1 in HPV-093 (NCT03355820) Study — 223 Participants
Infertility
Primary: Number of Oocytes Retrieved — 7.1; 7.3; 6.6 Number of oocytes
Coronary Arteriosclerosis
Primary: Patency Rates — 38; 58; 6; 1 Participants
Back Pain · Neck Pain
Primary: Change in Pain on Movement (POM) With Regard to the Worst Procedure (WP) Between Baseline and Day 2 (Morning, 2 Hours After Drug Intake) — 1.712; 1.998; 1.869 Unit on…
Infections, Meningococcal
Primary: Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6…
Coronary Artery Bypass · Myocardial Ischemia · Myocardial Infarction
Primary: Number of Participants With Perioperative Myocardial Infarction, Postoperative Heart Failure or Postoperative Mortality — 31; 25 Participants
Infertility, Female
Primary: Oocytes (Intention-to-Treat, ITT) — 12.16; 11.62 Number of retrieved oocytes — p=0.002
Glabellar Lines
Primary: Superiority Analysis of The Percentage of Responders Measured by the Investigator's Live Assessment (ILA) at Maximum Frown at Cycle 1, Day 29 (DB Period). — 95.2; 0.9…
Lymphoma, Mucosa-Associated Lymphoid Tissue
Primary: Event-free-survival (EFS) — 51; 68; 51 percentage of patients